Stay updated with breaking news from Affordability Task. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
2023 was an important year for patients with sickle cell disease. The FDA approved Vertex’s “Casgevy,” a CRISPR-based therapy for the treatment of sickle cell disease marking it as the first genetically edited therapy to reach the general market.
2023 was an important year for patients with sickle cell disease. The FDA approved Vertex’s “Casgevy,” a CRISPR-based therapy for the treatment of sickle cell disease marking it as the first genetically edited therapy to reach the general market.
The UK’s Medicines and Healthcare products Agency approved the first-ever CRISPR-based gene editing treatment for blood disorders.
The city will be on the hunt for fresh funding as it looks to renew its downtown office conversion.
The city will be on the hunt for fresh funding as it looks to renew its downtown office conversion.